EpiVax, Inc. today announced a collaborative research agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) aimed at evaluating EpiVax’s proprietary Tregitope technology, which could potentially reduce detrimental immune responses to certain drugs. In the course of the Roche-EpiVax collaboration, the EpiVax Tregitope technology will be evaluated for its effect on the immunogenicity of protein therapeutics.
(Vocus) December 2, 2009 -- Together, EpiVax and Roche will carry out in silico, in vitro and in vivo experiments aimed at establishing proof of concept. Under the agreement, Roche has a nonexclusive option to use Tregitope technology in its pipeline of protein therapeutic drugs with a right to a license the technology for specific products under pre-negotiated terms.
"Roche brings a wealth of experience, clinical expertise and resources to this collaboration. Working together, it is our intent to integrate the Tregitope technology into drugs that will improve human health on a global scale,” said Dr. Anne De Groot, CEO and CSO of EpiVax
Because Tregitope uses the body’s own natural responses to induce tolerance, treatments incorporating Tregitope have the potential to be far safer than administration of protein therapeutics with systemic immunosuppressants, a clinical approach to addressing immunogenicity that is relatively common. EpiVax believes the Tregitope technology could also be used for treatment of a broad range of auto-immune disorders as well as applications in the treatment of allergy, transplant, deimmunization
Copyright©2009 Vocus, Inc.
All rights reserved